Similar cell surface expression of β2-microglobulin-free heavy chains by HLA-B27 subtypes differentially associated with ankylosing spondylitis

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 3290-3299

  Vázquez, Miriam N ^a   López De Castro, José A ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; HLA B27 ANTIGEN;

ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTATION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISSOCIATION CONSTANT; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEAVY CHAIN; HLA SYSTEM; HUMAN; HUMAN CELL; LIGAND BINDING; LYMPHOID CELL; MOLECULAR RECOGNITION; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ANTIGENS, SURFACE; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CELL LINE; DIMERIZATION; DISEASE SUSCEPTIBILITY; FLOW CYTOMETRY; HLA-B27 ANTIGEN; HUMANS; LYMPHOCYTES; SPONDYLITIS, ANKYLOSING; TRANSFECTION;

EID: 26844446015     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21284     Document Type: Article

References (51)

1. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323-58.
2. Ljunggren HG, Stam NJ, Ohlen C, Neefjes JJ, Hoglund P, Heemels MT, et al. Empty MHC class I molecules come out in the cold. Nature 1990;346:476-80.
3. Bird LA, Peh CA, Kollnberger S, Elliott T, McMichael AJ, Bowness P. Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur J Immunol 2003;33:748-59.
4. Paulsson KM, Wang P. Quality control of MHC class I maturation. FASEB J 2004;18:31-8.
5. 2-microglobulin. Hum Immunol 2000;61:1197-201.
6. 2- microglobulin complex. Immunogenetics 2001;53:440-6.
7. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973; 1:904-7.
8. Brewerton DA, Caffrey M, Nicholls A, Walters D, Oates JK, James DC. Reiter's disease and HL-A 27. Lancet 1973;2:996-8.
9. Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990;11:137-42.
10. Mear JP, Schreiber KL, Munz C, Zhu X, Stevanovic S, Rammensee HG, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999;163:6665-70.
11. Colbert RA. HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum? Mol Med Today 2000;6:224-30.
12. Dangoria NS, DeLay ML, Kingsbury DJ, Mear JP, Uchanska-Ziegler B, Ziegler A, et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem 2002;277:23459-68.
13. Kollnberger S, Bird L, Sun MY, Retiere C, Braud VM, McMichael A, et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 2002;46:2972-82.
14. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001;167:5543-7.
15. 2m-deposition disease? Trends Immunol 2003;24:73-6.
16. Ramos M, Lopez de Castro JA. HLA-B27 and the pathogenesis of spondyloarthritis. Tissue Antigens 2002;60:191-205.
17. Lopez-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis: evidence for new associations. Tissue Antigens 1995;45:169-76.
18. Nasution AR, Mardjuadi A, Kunmartini S, Suryadhana NG, Setyohadi B, Sudarsono D, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997;24:1111-4.
19. Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH. Possible protective role of HLA-B*2706 for ankylosing spondylitis. Tissue Antigens 1997;49:67-9.
20. D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zuccarelli A, Bitti PP, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25:3199-201.
21. Mathieu A, Sorrentino R. HLA-B*2709 and spondylarthropathies: comment on the concise communication by Olivieri et al [letter]. Arthritis Rheum 2003;48:866-7.
22. Fiorillo MT, Cauli A, Carcassi C, Bitti PP, Vacca A, Passiu G, et al. Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for disease pathogenesis. Arthritis Rheum 2003; 48:1385-9.
23. Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997;49: 116-23.
24. Varnavidou-Nicolaidou A, Karpasitou K, Georgiou D, Stylianou G, Kokkofitou A, Michalis C, et al. HLA-B27 in the Greek Cypriot population: distribution of subtypes in patients with ankylosing spondylitis and other HLA-B27-related diseases: the possible protective role of B*2707. Hum Immunol 2004;65:1451-4.
25. Fiorillo MT, Meadows L, D'Amato M, Shabanowitz J, Hunt DF, Apella E, et al. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 1997;27:368-73.
26. Ramos M, Paradela A, Vazquez M, Marina A, Vazquez J, Lopez de Castro JA. Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability. J Biol Chem 2002;277: 28749-56.
27. Sesma L, Montserrat V, Lamas JR, Marina A, Vazquez J, Lopez de Castro JA. The peptide repertoires of HLA-B27 subtypes differentially associated with spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions. J Biol Chem 2002;277:16744-9.
28. Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, Lopez de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002;277:37573-81.
29. Zemmour J, Little AM, Schendel DJ, Parham P. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992;148:1941-8.
30. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986;5:943-9.
31. Boyle LH, Goodall JC, Gaston JS. Major histocompatibility complex class I-restricted alloreactive CD4 T cells. Immunology 2004;112:54-63.
32. Parham P, Bodmer WF. Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. Nature 1978;276:397-9.
33. Ellis SA, Taylor C, McMichael A. Recognition of HLA-B27 and related antigens by a monoclonal antibody. Hum Immunol 1982; 5:49-59.
34. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: new tools for genetic analysis. Cell 1978;14:9-20.
35. 2- microglobulin recognized by mouse monoclonal antibody BBM.1. J Biol Chem 1983;258:6179-86.
36. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
37. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998;160:4951-60.
38. Alvarez I, Marti M, Vazquez J, Camafeita E, Ogueta S, Lopez de Castro JA. The Cys-67 residue of HLA-B27 influences cell surface stability, peptide specificity, and T-cell antigen presentation. J Biol Chem 2001;276:48740-7.
39. Lopez de Castro JA, Alvarez I, Marcilla M, Paradela A, Ramos M, Sesma L, et al. HLA-B27: a registry of constitutive peptide ligands. Tissue Antigens 2004;63:424-45.
40. 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999;162:5045-8.
41. Antoniou AN, Ford S, Taurog JD, Butcher GW, Powis SJ. Formation of HLA-B27 homodimers and their relationship to assembly kinetics. J Biol Chem 2004;279:8895-902.
42. May E, Dorris ML, Satumtira N, Iqbal I, Rehman MI, Lightfoot E, et al. CD8 α β cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J Immunol 2003;170:1099-105.
43. Lamas JR, Paradela A, Roncal F, Lopez de Castro JA. Modulation at multiple anchor positions of the peptide specificity of HLA-B27 subtypes differentially associated with ankylosing spondylitis. Arthritis Rheum 1999;42:1975-85.
44. Hulsmeyer M, Hilling RC, Volz A, Ruhl M, Schroder W, Saenger W, et al. HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations. J Biol Chem 2002;277: 47844-53.
45. Hillig RC, Huelsmeyer M, Saenger W, Welfle K, Misselwitz R, Welfle H, et al. Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association. J Biol Chem 2004;279: 652-63.
46. Neisig A, Wubbolts R, Zang X, Melief C, Neefjes J. Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J Immunol 1996; 156:3196-206.
47. Turnquist HR, Thomas HJ, Prilliman KR, Lutz CT, Hildebrand WH, Solheim JC. HLA-B polymorphism affects interactions with multiple endoplasmic reticulum proteins. Eur J Immunol 2000;30: 3021-8.
48. Turnquist HR, Schenk EL, McIlhaney MM, Hickman HD, Hildebrand WH, Solheim JC. Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics 2002;53:830-4.
49. Hildebrand WH, Turnquist HR, Prilliman KR, Hickman HD, Schenk EL, McIlhaney MM, et al. HLA class I polymorphism has a dual impact on ligand binding and chaperone interaction. Hum Immunol 2002;63:248-55.
50. Carreno BM, Hansen TH. Exogenous peptide ligand influences the expression and half-life of free HLA class I heavy chains ubiquitously detected at the cell surface. Eur J Immunol 1994;24: 1285-92.
51. Day PM, Yewdell JW, Porgador A, Germain RN, Bennink JR. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc Natl Acad Sci U S A 1997;94:8064-9.